The IVF outcome counseling based on the model combining DHEAS and age in patients with low AMH prior to the first cycle of GnRH antagonist protocol of ovarian stimulation

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Alebić, Miro Šimun ^a   Stojanović, Nataša ^a   Žuvić Butorac, Marta ^b  

^a University of Zagreb   (Croatia)

^b University of Rijeka   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN ANTAGONIST; MUELLERIAN INHIBITING FACTOR; PRASTERONE SULFATE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; COUNSELING; FEMALE; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; THERAPY EFFECT;

EID: 84875425650     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/637919     Document Type: Article

References (25)

1. Templeton A., Morris J. K., Parslow W., Factors that affect outcome of in-vitro fertilisation treatment. Lancet 1996 348 9039 1402 1406 2-s2.0-0030599530 10.1016/S0140-6736(96)05291-9 (Pubitemid 26395234)
2. Verberg M. F. G., Eijkemans M. J. C., Macklon N. S., Heijnen E. M. E. W., Fauser B. C. J. M., Broekmans F. J., Predictors of ongoing pregnancy after single-embryo transfer following mild ovarian stimulation for IVF. Fertility and Sterility 2008 89 5 1159 1165 2-s2.0-43449113546 10.1016/j.fertnstert.2007.05. 020 (Pubitemid 351671732)
3. Nelson S. M., Yates R. W., Lyall H., Jamieson M., Traynor I., Gaudoin M., Mitchell P., Ambrose P., Fleming R., Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Human Reproduction 2009 24 4 867 875 2-s2.0-64949163396 10.1093/humrep/den480
4. Oudendijk J. F., Yarde F., Eijkemans M. J., Broekmans F. J., Broer S. L., The poor responder in IVF: is the prognosis always poor?: a systematic review. Human Reproduction Update 2012 18 1 11
5. Van Rooij I. A. J., Broekmans F. J. M., Te Velde E. R., Fauser B. C. J. M., Bancsi L. F. J. M. M., De Jong F. H., Themmen A. P. N., Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Human Reproduction 2002 17 12 3065 3071 2-s2.0-0036902652 (Pubitemid 35469254)
6. Nelson S. M., Yates R. W., Fleming R., Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Human Reproduction 2007 22 9 2414 2421 2-s2.0-34548064239 10.1093/humrep/dem204 (Pubitemid 47289055)
7. Broer S. L., Mol B. W. J., Hendriks D., Broekmans F. J. M., The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertility and Sterility 2009 91 3 705 714 2-s2.0-61349180236 10.1016/j.fertnstert.2007.12.013
8. La Marca A., Sighinolfi G., Radi D., Argento C., Baraldi E., Artenisio A. C., Stabile G., Volpe A., Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Human Reproduction Update 2010 16 2 113 130 2-s2.0-77949454760 10.1093/humupd/dmp036
9. Lekamge D. N., Barry M., Kolo M., Lane M., Gilchrist R. B., Tremellen K. P., Anti-Müllerian hormone as a predictor of IVF outcome. Reproductive BioMedicine Online 2007 14 602 610 2-s2.0-34248659394
10. La Marca A., Nelson S. M., Sighinolfi G., Manno M., Baraldi E., Roli L., Xella S., Marsella T., Tagliasacchi D., D'Amico R., Volpe A., Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reproductive BioMedicine Online 2011 22 4 341 349 2-s2.0-79953736756 10.1016/j.rbmo.2010.11.005
11. Nelson S. M., Anderson R. A., Broekmans F. J., Raine-Fenning N., Fleming R., La Marca A., Anti-Müllerian hormone: clairvoyance or crystal clear? Human Reproduction 2012 27 631 636
12. Yates A. P., Rustamov O., Roberts S. A., Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Human Reproduction 2011 26 2353 2362
13. Wallace A. M., Faye S. A., Fleming R., Nelson S. M., A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II). Annals of Clinical Biochemistry 2011 48 370 373
14. CLSI Protocol EP15-A2-User verification of performance for precision and trueness. Approved Guideline 2005 25 17
15. Cook N. R., Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007 115 7 928 935 2-s2.0-33847109797 10.1161/CIRCULATIONAHA.106.672402 (Pubitemid 46294733)
16. Hendriks D. J., Te Velde E. R., Looman C. W. N., Bancsi L. F. J. M. M., Broekmans F. J. M., Expected poor ovarian response in predicting cumulative pregnancy rates: a powerful tool. Reproductive BioMedicine Online 2008 17 5 727 736 2-s2.0-56749141013
17. Ferraretti A. P., La Marca A., Fauser B. C. J. M., Tarlatzis B., Nargund G., Gianaroli L., ESHRE consensus on the definition of "poor response" to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction 2011 26 7 1616 1624 2-s2.0-79959426436 10.1093/humrep/der092
18. Weghofer A., Dietrich W., Barad D. H., Gleicher N., Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. Human Reproduction 2011 26 7 1905 1909 2-s2.0-79959428032 10.1093/humrep/der134
19. Lee T. H., Liu C. H., Huang C. C., Hsieh K. C., Lin P. M., Lee M. S., Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reproductive Biology and Endocrinology 2009 7, article 100 2-s2.0-70449359765 10.1186/1477-7827-7-100
20. Casson P. R., Lindsay M. S., Pisarska M. D., Carson S. A., Buster J. E., Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction 2000 15 10 2129 2132 2-s2.0-0033781105
21. Orentreich N., Brind J. L., Rizer R. L., Vogelman J. H., Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Journal of Clinical Endocrinology and Metabolism 1997 82 2396 2402
22. Labrie F., Bélanger A., Cusan L., Gomez J. L., Candas B., Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Journal of Clinical Endocrinology and Metabolism 1997 82 8 2396 2402 2-s2.0-0030739131 10.1210/jc.82.8.2396 (Pubitemid 27337846)
23. von Mühlen D., Laughlin G. A., Kritz-Silverstein D., Barrett-Connor E., The Dehydroepiandrosterone And WellNess (DAWN) study: research design and methods. Contemporary Clinical Trials 2007 28 2 153 168 2-s2.0-33845594342 10.1016/j.cct.2006.04.009 (Pubitemid 44937875)
24. Gleicher N., Barad D. H., Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reproductive Biology and Endocrinology 2011 9, article 67 2-s2.0-79955954716 10.1186/1477-7827-9-67
25. Broer S. L., Mol B., Dólleman M., Fauser B. C., Broekmans F. J., The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Current Opinion in Obstetrics and Gynecology 2010 22 193 201